IP Library Granted Patent US 8,263,749
Granted Patent B2
US 8,263,749 · App. 13/287,467 · Granted Sep 11, 2012

Imatinib immunoassay

Assignee: Saladax Biomedical Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,749
App. No.
13/287,467
Granted
Sep 11, 2012
Kind
B2
Abstract

Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Claims (22)

1. An antibody which binds selectively to imatinib and its pharmacologically active salts without having any substantial cross-reactivity with N-desmethyl imatinib.

2. The antibody of claim 1 , wherein said antibody is derived from mice, rabbits or rats.

3. The antibody of claim 1 , wherein said antibody is a polyclonal antibody.

4. The antibody of claim 3 , wherein said antibody is a monoclonal antibody.

5. The antibody of claim 1 , wherein said antibody is derived from an immunogen of an immunogenic carrier containing a polymer having either a reactive thiol or amino group conjugated with a compound of the formula:

or its pharmacologically active salts;

wherein Y is an organic spacing group;

X is a terminal functional group capable of binding to said carrier through said amino or thiol group and;

p is an integer from 0 to 1.

6. A kit for determining the presence of imatinib or its pharmacologically active salts in a patient sample comprising reagents in separate containers, one of the reagents being a conjugate of a carrier containing a polymer having either a reactive thiol or amino group with a compound of the formula:

or its pharmacologically active salts;

wherein Y is an organic spacing group;

X is a terminal functional group capable of binding to said carrier through said amino or thiol group and;

p is an integer from 0 to 1;

and a second reagent in a separate container being an antibody which binds selectively to imatinib and its pharmacologically active salts without having any substantial cross-reactivity with the pharmacologically inactive metabolites of imatinib.

7. The kit of claim 6 , wherein said conjugate is present in a predetermined amount in said first container.

8. The kit of claim 7 , wherein said kit is used to determine the amount of imatinib and its pharmacologically active salts in said sample.

9. The kit of claim 8 , wherein, said antibody is generated from an immunogenic carrier containing a polymer having either a reactive thiol or amino group linked to a compound of the formula:

or its pharmacologically active salts;

wherein Y is an organic spacing group;

X is a terminal functional group capable of binding to said carrier through said amino or thiol group and;

p is an integer from 0 to 1.

Assignments (1)
SECURITY INTEREST Recorded Nov 17, 2015
From: SALADAX BIOMEDICAL, INC.
To: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Reel/Frame 037126/0733 →
Continuity (2)
Division 12543699 · Aug 19, 2009
Related Publication 20120045782A1 · Feb 23, 2012